The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity

Yingyu Chen(Fujian Medical University), Qizhen Shi(Children's Hospital of Wisconsin), Jianda Hu(Fujian Medical University), Jocelyn A. Schroeder(Medical College of Wisconsin), Juan Chen(Chinese Academy of Sciences), Xiaofeng Luo(Fujian Medical University), Christina K. Baumgartner(AbbVie (United States)), Robert R. Montgomery(Scripps Health)

Blood

December 15, 2015

10.1182/blood-2015-08-662916

Cited by 25

Related Papers

Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council

|Journal of Pain|2016|3.1k

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

|The Lancet Haematology|2019|248

Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma

|Cancer Cell|2020|234

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies

|Journal of Clinical Investigation|2006|188

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

|Nature|2023|170